| Symbol | CUE |
|---|---|
| Name | CUE BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21 ERIE STREET, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 949-2680 |
| Fax | — |
| — | |
| Website | https://www.cuebiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001645460 |
| Description | Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Additional info from NASDAQ: |
Ahlers James M 🟢 acquired 76.5K shares (1 derivative) of Cue Biopharma, Inc. (CUE) at $30.40 ($1.6M) Transaction Date: Jul 30, 2026 | Filing ID: 000006
Read moreNew Form 3 - Cue Biopharma, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001320383-26-000004 <b>Size:</b> 16 KB
Read moreCue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Read moreNew Form 4/A - Cue Biopharma, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001725092-26-000009 <b>Size:</b> 9 KB
Read moreNew Form D - Cue Biopharma, Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001645460-26-000004 <b>Size:</b> 11 KB
Read moreBorie Dominique Christian 🟢 acquired 94.5K shares (1 derivative) of Cue Biopharma, Inc. (CUE) at $30.92 ($1.9M) Transaction Date: Jul 13, 2026 | Filing ID: 000006
Read moreNew Form 3 - Cue Biopharma, Inc. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0002008790-26-000004 <b>Size:</b> 16 KB
Read moreNew Form EFFECT - Cue Biopharma, Inc. <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 9999999995-26-002180 <b>Size:</b> 1 KB
Read moreNew Form EFFECT - Cue Biopharma, Inc. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 9999999995-26-002046 <b>Size:</b> 1 KB
Read moreNew Form 3 - Cue Biopharma, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0002138368-26-000003 <b>Size:</b> 3 KB
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KEYTRUDA ®( Pembrolizumab) | DRUG | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT06963814 |
| Placebo | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06657703 |
| HC022 | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06657703 |
| Docetaxel | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07381829 |
| Carboplatin/Cisplatin | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07381829 |
| Etoposide | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07381829 |
| Pemetrexed | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07381829 |
| Paclitaxel (Chemotherapy) | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07381829 |
| HC006 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06304571 |
| Capecitabine | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07477743 |
| Oxaliplatin | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07477743 |
| Paclitaxel | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07477743 |
| HC010 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06307925 |